OXB Cuts Viral Vector Development Timelines by Up to 50% with Fast-Track Service
Event summary
- OXB launched a fast-track offering for AAV and lentiviral vector platforms on April 13, 2026.
- The service can reduce the timeline to GMP manufacturing from ~15 months to as little as seven months for AAV vectors.
- For lentiviral vectors, the timeline is shortened from 12-18 months to as little as nine months.
- The offering leverages OXB’s proprietary inAAVate™ and LentiVector™ platforms.
The big picture
OXB’s fast-track service addresses a critical bottleneck in the cell and gene therapy sector, where development timelines often delay clinical milestones. By leveraging proprietary platforms and process efficiencies, OXB aims to reinforce its position as a trusted CDMO, catering to biotechs under time or financial pressure. This move aligns with broader industry trends toward accelerating therapeutic development to meet unmet medical needs.
What we're watching
- Market Adoption
- How quickly biotechs with timeline constraints will adopt OXB’s fast-track offering.
- Competitive Response
- Whether competitors will introduce similar expedited services to maintain market share.
- Operational Scaling
- The pace at which OXB can scale this offering without compromising quality or efficiency gains.
Related topics